Illumina, Inc. (ILMN)

Market Cap	15.29B
Revenue (ttm)	4.28B
Net Income (ttm)	1.26B
Shares Out	153.70M
EPS (ttm)	7.91
PE Ratio	12.53
Forward PE	21.25
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,739
Open	98.20
Previous Close	97.38
Day's Range	98.02 - 99.30
52-Week Range	68.70 - 156.66
Beta	1.37
Analysts	Buy
Price Target	127.00 (+27.65%)
Earnings Date	Jul 31, 2025

About ILMN

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 28, 2000
• Employees: 10,370
• Stock Exchange: NASDAQ
• Ticker Symbol: ILMN
• Website: https://www.illumina.com

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Analyst Forecast

According to 17 analysts, the average rating for ILMN stock is "Buy." The 12-month stock price target is $127.0, which is an increase of 27.65% from the latest price.

Price Target

$127.0

(27.65% upside)

Analyst Consensus: Buy